Toniv,

It's not just the name change, but the ENTIRE transaction that still needs to close. So please, at least wait until this happens before you let any frustration build. From the Dec 2nd 2015 Management Information Circular:

"In accordance with the Asset Purchase Agreement, the Purchase Price is subject to adjustment based on any changes to working capital of the Corporation and the Assumed Liabilities between the date of the Asset Purchase Agreement and the effective date of the Transaction, which is currently anticipated to be February 1, 2016. In particular, the Corporation is frequently in discussions with third parties regarding potential licensing and/or royalty arrangements which may require adjustments to the Purchase Price if any such transaction is completed prior to the effective date of the Transaction."

From the Upcoming Milestone slide and Clinical Development Plan slide of the Zenith Corporate update, we know that Zenith has already filed an IND application and sounds like it is approved (or nearly approved). They also already have the lead investigators lined up to head the prostate/solid tumor trial. The next steps are to initiate the clinical trial for solid tumors in H1 2016 and reach proof of concept by 2H 2016 and expand the trial to include combination therapies by H2 2016. We should see a listing on ClinicalTrials.gov when this trial begins and very likely will hear an update from Zenith as well when this trial officially begins. It has only been a few weeks since this presentation was given at Biotech Showcase. It is still Q1 2016. Have some patience and let things unfold!

Best regards,

BearDownAZ